Preclinical
As the COVID-19 pandemic continues with surges in the U.S. in unvaccinated people, biopharma companies are still working on new vaccines and therapies against the disease.
In a preclinical study published in PNAS, scientists from Feinstein Institutes for Medical Research presented a new approach to treating diseases that involve inflammation and pain, like arthritis.
Sierra will have access to AZD5153, a potent and selective BRD4 BET inhibitor, to initiate a study that combines the said component with momelotinib for treating patients with myelofibrosis.
Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
The company announced its Malaria project, part of the “eradicateMalaria” initiative led by the kENUP Foundation.
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to knock out the Fel d 1 protein completely from the cats.
Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.
PRESS RELEASES